Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees

Executive Summary

The Generic Pharmaceutical Association is balking at continuing to negotiate the design of a biosimilar user fee program that is independent of other user fees and has its own baseline appropriations trigger.
Advertisement

Related Content

Biosimilar Product Development Meetings With FDA To Be Flexible Under User Fee Program
Burr Warns User Fee Renewal Could Be Difficult Without Performance Measure Improvements
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
Biosimilar User Fees Would Be Same As BLAs, Only Earlier

Topics

Advertisement
UsernamePublicRestriction

Register

PS053698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel